©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2025; 31(43): 111433
Published online Nov 21, 2025. doi: 10.3748/wjg.v31.i43.111433
Published online Nov 21, 2025. doi: 10.3748/wjg.v31.i43.111433
Pancreatic cancer in 2025: Have we found a solution?
Valeria Tonini, Manuel Zanni, Department of Medical and Surgical Sciences, University of Bologna, Bologna 40138, Emilia-Romagna, Italy
Co-first authors: Valeria Tonini and Manuel Zanni.
Author contributions: Tonini V and Zanni M contributed equally to the writing of the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Valeria Tonini, MD, Adjunct Associate Professor, Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 9, Bologna 40138, Emilia-Romagna, Italy. valeria.tonini@unibo.it
Received: June 30, 2025
Revised: July 28, 2025
Accepted: October 9, 2025
Published online: November 21, 2025
Processing time: 144 Days and 7.7 Hours
Revised: July 28, 2025
Accepted: October 9, 2025
Published online: November 21, 2025
Processing time: 144 Days and 7.7 Hours
Core Tip
Core Tip: Pancreatic cancer is still one of the neoplasms with the worst prognosis. Late presentation at an unresectable or metastatic stage precluding surgery, aggressive biology, and resistance to antiblastic drugs make this disease a fearsome challenge. This review aims to investigate new strategies for early diagnosis and new therapeutic hopes for improving the still tragic outcomes.